Remove tag
article thumbnail

Can gene therapies for haemophilia defend their high price tags?

Pharmaceutical Technology

In the EU however, two years later, the European Commission awarded a conditional marketing authorisation for Roctavian. The European Commission withdrew the marketing authorisation of Zynteglo, at the request of bluebird bio, in March 2022. million price tag. million ($1.5 million ($1.8 million at the time).

article thumbnail

Lilly wades deeper into copycat insulin market, scoring interchangeability tag for Lantus biosim

Fierce Pharma

Lilly wades deeper into copycat insulin market, scoring interchangeability tag for Lantus biosim. fkansteiner. Fri, 11/18/2022 - 11:01.

Insulin 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biogen’s Alzheimer’s drug: What’s the price tag on hope?

World of DTC Marketing

If the drug is approved you can bet that it’s going to carry a huge price tag. It could carry a price tag as high as $50,000-a-year per patient, according to drug analysts, adding billions of dollars to the nation’s health tab. . Will they follow the science or will they put a price tag on hope?

Drugs 187
article thumbnail

With European approval secured, BioMarin puts roughly $1.5M price tag on hemophilia gene therapy

Bio Pharma Dive

On a conference call, BioMarin executives revealed the anticipated price for Roctavian and the company's initial launch plans, which include pay-for-performance deals customized to different markets.

article thumbnail

Global (68M) cardiomyopathies market projected to grow to $9.63bn by 2031

Pharmaceutical Technology

In an expanded version of the sales forecast from GlobalData’s June 2022 publication, Cardiomyopathies: Global Drug Forecast and Market Analysis , the global cardiomyopathies market is expected to grow from $3.07bn last year to $9.63bn in 2031. The second highest contributing market is APAC, generating 33.2%

Marketing 130
article thumbnail

FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag

pharmaphorum

AZ has already licensed rights to HER2-targeting drug Enhertu (trastuzumab deruxtecan) – which is already on the market for HER2-positive breast and gastric cancers – as well as investigational TROP2 ADC datopotamab deruxtecan in two multibillion-dollar deals. Daiichi Sankyo and AZ are close collaborators in the ADC arena.

Drugs 71
article thumbnail

FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag

pharmaphorum

Instead, the FDA granted Aduhelm a conditional approval, allowing it to be prescribed and used while Biogen conducts a post-marketing, phase 4 confirmatory study – which could take years to complete. If benefit is not verified, we can act to remove the drug from the market. — Brad Loncar (@bradloncar) June 7, 2021.

Drugs 98